Pharmamarketeer
overig

Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy

20 maart 2018
Pharmafile

Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a recent Phase 3 study, showing strong results in the treatment of moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)